{
    "table_id": "finqa_a31d6f397d",
    "source": "finqa",
    "original_metadata": {
        "source_dataset": "finqa",
        "document_id": "REGN/2010/page_72.pdf-3",
        "pre_text_caption_evidence": [
            "we prepare estimates of research and development costs for projects in clinical development , which include direct costs and allocations of certain costs such as indirect labor , non-cash compensation expense , and manufacturing and other costs related to activities that benefit multiple projects , and , under our collaboration with bayer healthcare , the portion of bayer healthcare 2019s vegf trap-eye development expenses that we are obligated to reimburse .",
            "our estimates of research and development costs for clinical development programs are shown below : project costs year ended december 31 , increase ( decrease ) ( in millions ) 2009 2008 ."
        ],
        "question": "what was the percentage change in research and development costs related to arcalyst ae from 2008 to 2009?"
    },
    "dimensions": {
        "rows": 7,
        "columns": 4
    },
    "schema": {
        "columns": [
            "project costs ( in millions )",
            "project costs 2009",
            "2008",
            "( decrease )"
        ],
        "dtypes": {
            "project costs ( in millions )": "object",
            "project costs 2009": "object",
            "2008": "object",
            "( decrease )": "object"
        }
    }
}